Vliv adjuvantně podávaného aripiprazolu na metabolické příznaky u nemocných schizofrenií léčených klozapinem

  • Minářová K
  • Masopust J
  • Protopopová-Kalnická D
 et al. 
  • 2


    Mendeley users who have this article in their library.
  • 0


    Citations of this article.


Treatment with clozapine is indicated in the pharmacoresistant schizophrenia. Frequent adverse effects associated with clozapine include weight gain and metabolic adverse effects. We present a case series of 13 patients treated with the combination of clozapine and aripiprazole. After one year of follow-up we have observed a significant weight loss and alleviation of psychopathology in the treated individuals. In accordance with the literature we suggest the benefit of described combination in cases where the clozapine can’t be switched to another antipsychotic and the patients already have some of the cardiovascular risk factors. (PsycINFO Database Record (c) 2014 APA, all rights reserved). (journal abstract)

Author-supplied keywords

  • Aripiprazole
  • Clozapine
  • Metabolic symptoms
  • Schizophrenia

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • SGR: 84875030581
  • PUI: 368530379
  • SCOPUS: 2-s2.0-84875030581
  • ISSN: 12120383


  • Kristýna Minářová

  • Jiří Masopust

  • Dita Protopopová-Kalnická

  • Radovan Malý

  • Jan Bažant

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free